Free Trial
ASX:BOT

Botanix Pharmaceuticals (BOT) Stock Price, News & Analysis

Botanix Pharmaceuticals logo

About Botanix Pharmaceuticals Stock (ASX:BOT)

Advanced Chart

Key Stats

Today's Range
N/A
50-Day Range
N/A
52-Week Range
N/A
Volume
1.63 million shs
Average Volume
N/A
Market Capitalization
$912.82 million
P/E Ratio
N/A
Dividend Yield
2.96%
Price Target
N/A
Consensus Rating
N/A

Company Overview

Botanix Pharmaceuticals Limited engages in the research and development of dermatology and antimicrobial products in Australia. The company engages in development of novel treatments for common skin diseases and infections. Its product pipeline includes Sofpironium Bromide, a drug in development for the treatment of primary axillary hyperhidrosis that has completed Phase 3 clinical programs; BTX 1503, a transdermal gel formulation for the treatment of serious acne in adults and teenagers that has completed Phase II clinical trials; BTX 1801, which has completed Phase IIb clinical trials for the treatment of staphylococcus aureus and methicillin resistant staphylococcus aureus; BTX 1702 that is in Phase II clinical trials for the treatment of papulopustular rosacea; and BTX 1204A for the treatment of atopic dermatitis. Botanix Pharmaceuticals Limited was incorporated in 1984 and is based in Leederville, Australia.

Receive BOT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Botanix Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

BOT Stock News Headlines

Silicon Valley Gold Rush
A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bill Gates has backed four companies in this space. The World Economic Forum calls it “the most exciting human discovery since fire.” Whitney Tilson believes this trend could mint a new class of wealthy investors—and he’s sharing one stock to watch now, for free.
See More Headlines

BOT Stock Analysis - Frequently Asked Questions

Botanix Pharmaceuticals Limited (ASX:BOT) issued its earnings results on Thursday, February, 28th. The company reported ($0.01) earnings per share (EPS) for the quarter. Botanix Pharmaceuticals had a negative trailing twelve-month return on equity of 18.00% and a negative net margin of 670.20%.

Based on aggregate information from My MarketBeat watchlists, some other companies that Botanix Pharmaceuticals investors own include Alphabet (GOOG), Meta Platforms (META), Arafura Rare Earths (ARU), Canopy Growth (CGC), Manning & Napier (MN), (STB.TO) (STB) and (YCB) (YCB).

Company Calendar

Last Earnings
2/28/2019
Today
5/05/2025

Industry, Sector and Symbol

Stock Exchange
ASX
Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
Current Symbol
ASX:BOT
CIK
N/A
Fax
N/A
Employees
11
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-13,870,000.00
Net Margins
-670.20%
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$2.07 million
Price / Cash Flow
1.50
Book Value
A$0.07 per share
Price / Book
N/A

Miscellaneous

Outstanding Shares
1,810,000,000
Free Float
N/A
Market Cap
$912.82 million
Optionable
Not Optionable
Beta
1.71
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for May 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

This page (ASX:BOT) was last updated on 5/5/2025 by MarketBeat.com Staff
From Our Partners